This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...

Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, today announced results from the PREDAPT ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving. Delays in molecular testing for ...